OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 9.38 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 366.00K shares.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was 0.00 shares.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-03-31 was 21.57K shares.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 387.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 9.38K shares 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 366.00K shares derived: sum of 2 quarters · filed 2026-03-04 | 366.00K shares derived: sum of 3 quarters · filed 2026-03-04 | 387.57K shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 366.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 366.00K shares derived: sum of 2 quarters · filed 2025-11-05 | 387.57K shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 21.57K shares 10-Q · filed 2025-08-04 | ||
| 2025-03-31 | 21.57K shares 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |